company background image
2666

Genertec Universal Medical Group SEHK:2666 Stock Report

Last Price

HK$4.85

Market Cap

HK$9.2b

7D

5.9%

1Y

-36.1%

Updated

28 Jun, 2022

Data

Company Financials +
2666 fundamental analysis
Snowflake Score
Valuation6/6
Future Growth1/6
Past Performance2/6
Financial Health3/6
Dividends2/6

2666 Stock Overview

Genertec Universal Medical Group Company Limited, together with its subsidiaries, offers financing and advisory services in the People’s Republic of China.

Genertec Universal Medical Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genertec Universal Medical Group
Historical stock prices
Current Share PriceHK$4.85
52 Week HighHK$7.94
52 Week LowHK$4.20
Beta0.62
1 Month Change-3.39%
3 Month Change-6.01%
1 Year Change-36.10%
3 Year Change-22.40%
5 Year Change-20.62%
Change since IPO-3.00%

Recent News & Updates

Jun 08
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group Company Limited ( HKG:2666 ) has announced that it will be increasing its dividend on...

Shareholder Returns

2666HK Diversified FinancialHK Market
7D5.9%0.7%1.7%
1Y-36.1%-10.5%-21.2%

Return vs Industry: 2666 underperformed the Hong Kong Diversified Financial industry which returned -10.5% over the past year.

Return vs Market: 2666 underperformed the Hong Kong Market which returned -21.2% over the past year.

Price Volatility

Is 2666's price volatile compared to industry and market?
2666 volatility
2666 Average Weekly Movement3.9%
Diversified Financial Industry Average Movement6.2%
Market Average Movement6.9%
10% most volatile stocks in HK Market13.8%
10% least volatile stocks in HK Market3.4%

Stable Share Price: 2666 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 2666's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198415,242Wang Wenbinghttps://www.umcare.cn

Genertec Universal Medical Group Company Limited, together with its subsidiaries, offers financing and advisory services in the People’s Republic of China. It operates in two segments, Finance and Advisory and Hospital Group. The Finance and Advisory segment provides direct finance leasing; sale and leaseback; factoring; operating leases; and advisory services.

Genertec Universal Medical Group Fundamentals Summary

How do Genertec Universal Medical Group's earnings and revenue compare to its market cap?
2666 fundamental statistics
Market CapCN¥7.82b
Earnings (TTM)CN¥1.84b
Revenue (TTM)CN¥9.57b

4.3x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2666 income statement (TTM)
RevenueCN¥9.57b
Cost of RevenueCN¥5.71b
Gross ProfitCN¥3.85b
Other ExpensesCN¥2.02b
EarningsCN¥1.84b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.97
Gross Margin40.26%
Net Profit Margin19.18%
Debt/Equity Ratio243.0%

How did 2666 perform over the long term?

See historical performance and comparison

Dividends

7.1%

Current Dividend Yield

30%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 2666 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2666?

Other financial metrics that can be useful for relative valuation.

2666 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ratio0.3x

Price to Earnings Ratio vs Peers

How does 2666's PE Ratio compare to its peers?

2666 PE Ratio vs Peers
The above table shows the PE ratio for 2666 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average17.7x
3877 CSSC (Hong Kong) Shipping
6.5x15.6%HK$8.7b
1606 China Development Bank Financial Leasing
3.2xn/aHK$14.0b
1563 International Alliance Financial Leasing
56.8xn/aHK$5.2b
1905 Haitong Unitrust International Financial Leasing
4.5xn/aHK$6.9b
2666 Genertec Universal Medical Group
4.3x16.1%HK$9.2b

Price-To-Earnings vs Peers: 2666 is good value based on its Price-To-Earnings Ratio (4.3x) compared to the peer average (17.7x).


Price to Earnings Ratio vs Industry

How does 2666's PE Ratio compare vs other companies in the Asian Diversified Financial Industry?

Price-To-Earnings vs Industry: 2666 is good value based on its Price-To-Earnings Ratio (4.3x) compared to the Hong Kong Diversified Financial industry average (8.4x)


Price to Earnings Ratio vs Fair Ratio

What is 2666's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2666 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.3x
Fair PE Ratio6.2x

Price-To-Earnings vs Fair Ratio: 2666 is good value based on its Price-To-Earnings Ratio (4.3x) compared to the estimated Fair Price-To-Earnings Ratio (6.2x).


Share Price vs Fair Value

What is the Fair Price of 2666 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2666 (HK$4.85) is trading below our estimate of fair value (HK$8.15)

Significantly Below Fair Value: 2666 is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: 2666 is good value based on its PEG Ratio (0.3x)


Discover undervalued companies

Future Growth

How is Genertec Universal Medical Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2666's forecast earnings growth (16.1% per year) is above the savings rate (1.5%).

Earnings vs Market: 2666's earnings (16.1% per year) are forecast to grow slower than the Hong Kong market (17.1% per year).

High Growth Earnings: 2666's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if 2666's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2666's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2666's Return on Equity is forecast to be low in 3 years time (16.7%).


Discover growth companies

Past Performance

How has Genertec Universal Medical Group performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


13.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 2666 has high quality earnings.

Growing Profit Margin: 2666's current net profit margins (19.2%) are lower than last year (20%).


Past Earnings Growth Analysis

Earnings Trend: 2666's earnings have grown by 13% per year over the past 5 years.

Accelerating Growth: 2666's earnings growth over the past year (11.4%) is below its 5-year average (13% per year).

Earnings vs Industry: 2666 earnings growth over the past year (11.4%) underperformed the Diversified Financial industry 20.2%.


Return on Equity

High ROE: 2666's Return on Equity (11.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Genertec Universal Medical Group's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 2666's short term assets (CN¥64.5B) exceed its short term liabilities (CN¥18.7B).

Long Term Liabilities: 2666's short term assets (CN¥64.5B) exceed its long term liabilities (CN¥33.5B).


Debt to Equity History and Analysis

Debt Level: 2666's net debt to equity ratio (229.7%) is considered high.

Reducing Debt: 2666's debt to equity ratio has reduced from 283.1% to 243% over the past 5 years.

Debt Coverage: 2666's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 2666's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is Genertec Universal Medical Group current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


7.12%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 2666's dividend (7.12%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.7%).

High Dividend: 2666's dividend (7.12%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.78%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 2666 has been paying a dividend for less than 10 years.

Growing Dividend: 2666's dividend payments have increased, but the company has only paid a dividend for 6 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (29.7%), 2666's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: 2666 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Wang Wenbing (48 yo)

5.33yrs

Tenure

CN¥1,629,000

Compensation

Mr. Wang Wenbing is General Manager of China Universal Leasing Co., Ltd since October 14, 2021. He has been Deputy General Manager of Genertec Universal Medical Group Company Limited (formerly known as Uni...


CEO Compensation Analysis

Compensation vs Market: Wang's total compensation ($USD243.44K) is below average for companies of similar size in the Hong Kong market ($USD548.84K).

Compensation vs Earnings: Insufficient data to compare Wang's compensation with company performance.


Leadership Team

Experienced Management: 2666's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: 2666's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genertec Universal Medical Group Company Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Genertec Universal Medical Group Company Limited
  • Ticker: 2666
  • Exchange: SEHK
  • Founded: 1984
  • Industry: Specialized Finance
  • Sector: Diversified Financials
  • Implied Market Cap: HK$9.174b
  • Shares outstanding: 1.89b
  • Website: https://www.umcare.cn

Number of Employees


Location

  • Genertec Universal Medical Group Company Limited
  • West Wing of Hademen Plaza
  • 4th, 5th, and 13th Floor
  • Beijing
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.